Innovotech targets personalized medicine for bacteria

Ken Boutilier doesn’t mince words. “We believe we are pursuing the greatest opportunity in microbiology since penicillin,” the CEO of Innovotech (TSX-V:IOT) says in an exclusive interview with biotuesdays.com. “That’s our fundamental belief. For as good as penicillin and subsequent antibiotics after it were, they missed a very important fact about bacteria: bacteria exist and [...]

Kane gets DispersinB from biotech plants

Kane Biotech (TSX-V:KNE) has confirmed the invention of biotech plants producing DispersinB antibiofilm enzyme, representing a proof of concept for developing bacterial disease-resistant agricultural crops. The Company said DispersinB-expressing plants are resistant to plant pathogens due to their ability to inhibit and disrupt biofilms. In addition, this biotech plant can also be used as a [...]

Kane technology makes two new scientific books

The R&D team at Kane Biotech (TSX-V:KNE) has authored two book chapters reviewing their biofilm research methodology and the antibiofilm-antimicrobial technology development strategy for bacterial infection control in two new scientific books. They are Antimicrobial Peptides: Methods and Protocols (Eds. Andrea Giuliani & Andrea C. Rinaldi) and Biofouling: Types, Impact and Anti-Fouling (Eds. Jun Chan [...]

In conversation with Gord Froehlich

After a 25-year stint with Monsanto Canada, where he rose to vice president, Gord Froehlich moved seamlessly into Kane Biotech (TSX-V: KNE) as VP of Business Development and then into the executive suite in 2006. While there is a myriad of differences between a biotech start-up and a global ag-biotech giant, Mr. Froehlich contends that [...]